This page shows the latest LigoCyte news and features for those working in and with pharma, biotech and healthcare.
Takeda acquired rights to TAK-214 when it bought US biopharma company LigoCyte in 2012 in a $60m deal and says it remains the only norovirus vaccine candidate in clinical development.
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
The LigoCyte acquisition is part of the expansion of Takeda's recently formed Vaccine Business Division. ... 64. LigoCyte /Takeda. Acquisition. VLP-based vaccines for GI &respiratory infections (lead product phase I/II).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...